



(12)

Rettet oversættelse af  
europæisk patentskrift

Patent- og  
Varemærkestyrelsen

(51) Int.Cl.: **A 61 K 47/55 (2017.01)** **A 61 K 31/135 (2006.01)** **A 61 K 31/165 (2006.01)**  
**A 61 K 47/60 (2017.01)** **A 61 K 47/65 (2017.01)**

(45) Oversættelsen bekendtgjort den: **2019-04-01**

(80) Dato for Den Europæiske Patentmyndigheds  
bekendtgørelse om meddelelse af patentet: **2018-12-05**

(86) Europæisk ansøgning nr.: **09760548.9**

(86) Europæisk indleveringsdag: **2009-10-20**

(87) Den europæiske ansøgnings publiceringsdag: **2011-08-03**

(86) International ansøgning nr.: **GB2009002484**

(87) Internationalt publikationsnr.: **WO2010046628**

(30) Prioritet: **2008-10-22 GB 0819287**

(84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR**

(73) Patenthaver: **Ellipses Pharma Limited, Berkeley Square House, Berkeley Square, London W1J 6BD, Storbritannien**

(72) Opfinder: **FALCONER, Robert, Andrew, 135 Nab Wood Drive, Nab Wood, West Yorkshire BD18 4EW, Storbritannien**  
**GILL, Jason, 29 Middleton Avenue, Rothwell Haigh, Leeds LS26 0SE, Storbritannien**  
**ATKINSON, Jennifer, 36a Church Street, Needingworth, Cambridgeshire PE27 4TB, Storbritannien**  
**LOADMAN, Paul, 110 Dalecroft Rise, Bradford BD15 9AX, Storbritannien**  
**BIBBY, Michael, 10 Clarendon Road, Eldwick, Bingley BD16 3DJ, Storbritannien**  
**PATTERSON, Laurence, Elder House, Lee Lane, Bingley, West Yorkshire BD16 1UP, Storbritannien**

(74) Fuldmægtig i Danmark: **Chas. Hude A/S, H.C. Andersens Boulevard 33, 1780 København V, Danmark**

(54) Benævnelse: **MMP-AKTIVEREDE VASCULÆRT ØDELÆGGENDE MIDLER**

(56) Fremdragne publikationer:  
**WO-A1-02/072620**  
**WO-A1-2005/023314**  
**WO-A2-01/68145**  
**WO-A2-2006/110476**  
**WO-A2-2008/125800**  
**ALBRIGHT C F ET AL: "Matrix-metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity" MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 4, no. 5, 1 May 2005 (2005-05-01), pages 751-760, XP002456667 ISSN: 1535-7163**  
**KLINE T ET AL: "Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9" MOLECULAR PHARMACEUTICS, AMERICAN CHEMICAL SOCIETY, US, vol. 1, no. 1, 12 January 2004 (2004-01-**

12), pages 9-22, XP007902392 ISSN: 1543-8384

KRATZ F ET AL: "Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 11, no. 15, 6 August 2001 (2001-08-06), pages 2001-2006, XP002208108 ISSN: 0960-894X

MANSOUR AHMED M ET AL: "A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 63, no. 14, 15 July 2003 (2003-07-15) , pages 4062-4066, XP002360787 ISSN: 0008-5472

KRATZ F ET AL: "PRODRUGS OF ANTHRACYCLINES IN CANCER CHEMOTHERAPY" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 13, no. 5, 1 January 2006 (2006-01-01), pages 477-523, XP009066220 ISSN: 0929-8673

CHAU Y ET AL: "SYNTHESIS AND CHARACTERIZATION OF DEXTRAN-PEPTIDE-METHOTREXATE CONJUGATES FOR TUMOR TARGETING VIA MEDIATION BY MATRIX METALLOPROTEINASE II AND MATRIX METALLOPROTEINASE IX" BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 15, no. 4, 1 July 2004 (2004-07-01), pages 931-941, XP001236871 ISSN: 1043-1802

DUBOWCHIK G M ET AL: "Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs" PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 83, 1 January 1999 (1999-01-01), pages 67-123, XP002391774 ISSN: 0163-7258

DAVIS P D ET AL: "ZD6126: A NOVEL VASCULAR-TARGETING AGENT THAT CAUSES SELECTIVE DESTRUCTION OF TUMOR VASCULATURE" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 62, no. 24, 15 December 2002 (2002-12-15), pages 7247-7253, XP001206293 ISSN: 0008-5472

E. O. Esbolaev ET AL: "C-10 AMINO ACID DERIVATIVES OF COLCHICINE", Chemistry of Natural Compounds, vol. 28, no. 3-4, 1 May 1992 (1992-05-01), pages 325-328, XP055058017, ISSN: 0009-3130, DOI: 10.1007/BF00630252

ESBOLAEV E O ET AL: "[10-CARBON DIPEPTIDE DERIVATIVES OF COLCHICINE]", KHIMIYA PRIRODNYKH SOEDINENII, O'ZBEKISTON RESPUBLIKASI FANLAR AKADEMIYASI, UZ, no. 1, 1 January 1989 (1989-01-01), pages 91-95, XP008161090, ISSN: 0023-1150

ESBOLAEV E O ET AL: "CYTOTOXIC ACTIVITY OF DIPEPTIDE DERIVATIVES OF COLCHICINE", [IZVESTIJA AKADEMII NAUK KAZACHSKOJ SSR / SERIJA BIOLOGICESKAYA] IZVESTIJA AKADEMII NAUK KAZACHSKOJ SSR, AKADEMIJA NAUK KAZACHSKOJ SSR <ALMA-ATA, KZ, no. 5, 1 January 1989 (1989-01-01), pages 83-86, XP008161093, ISSN: 0002-3183

ATKHOZHINA N A ET AL: "[10-amino analogs of colchicine: synthesis, structure and biological activity]", BIOORGANICHESKAYA KHIMIYA, IZDATEL'STVO NAUKA, RU, vol. 22, no. 5, 1 May 1996 (1996-05-01), pages 383-386, XP008161064, ISSN: 0132-3423

# DESCRIPTION

## Field of the Invention

**[0001]** The present invention relates to prodrugs of vascular disrupting agents and to the use of such compounds in the targeted treatment of cancer.

## Background to the Invention

**[0002]** Targeting tumour vasculature as a molecular approach to cancer chemotherapies is becoming one of the highest scientific priorities. Two drug models are emerging, i.e. one that prevents the formation of new blood vessels in the tumour (antiangiogenesis) and one that targets vascular destruction.

**[0003]** Disruption of even a small proportion of the tumour vasculature has been demonstrated to induce wide ranging tumour death and retardation of metastasis, since a single blood vessel is responsible for supporting the survival of many tumour cells. Endothelial cells, which form the major component of the vasculature, are highly dependent upon the tubulin cytoskeleton for their motility, invasion, attachment, alignment and proliferation (Denekamp, J, Br J Cancer, 45, 136-139 (1982)). Agents which disrupt the endothelial microtubule network will therefore cause a rapid collapse in tumour blood flow and a prolonged period of vascular shutdown, culminating in extensive tumour-cell necrosis (Tozer et al., Nat Rev Cancer, 5, 423-435 (2005); Lippert JW, Bioorg Med Chem, 15, 605-615 (2007)).

**[0004]** One of the most potent classes of cancer therapeutic drugs are the vascular disrupting agents (VDAs) which characteristically have good in vitro cell cytotoxicities but often show poor specificity for killing tumour over normal tissues in vivo. Furthermore, many VDAs such as the tubulin binding agents are water insoluble and require formulation before evaluation in the clinic. The present invention aims to address the aforementioned problems.

**[0005]** Colchicine and its analogues are potent VDAs causing haemorrhage and subsequent extensive necrosis in tumours (Tozer et al., Nat Rev Cancer, 5, 423-435 (2005)), as a direct consequence of tubulin binding and induction of microtubule depolymerisation (Chaudri et al., J Mol Biol, 303, 679-692 (2000)). Colchicine has not, however, shown intrinsic value as a clinically applicable anticancer therapeutic due to a high level of toxicity and consequent very narrow therapeutic index (Tozer et al., Nat Rev Cancer, 5, 423-435 (2005); Quinn et al., J Med Chem, 24, 636-639 (1981)). It would be desirable, therefore, to be able to target a VDA such as colchicine selectively to a tumour.

**[0006]** The present inventors have developed a system for overcoming the toxic effect of systemic administration of potent anti-cancer agents in particular vascular disrupting agents.

**Statements of the invention**

**[0007]** The present invention is based, at least in part, on the selection of a proteolytic cleavage site which allows for the selective release of a vascular disrupting agent, such as colchicine, at the tumour vasculature.

**[0008]** According to a first aspect of the invention there is provided a compound, or pharmaceutically acceptable salt thereof, comprising a vascular disrupting agent (VDA) associated with a peptide comprising a matrix metalloproteinase (MMP) proteolytic cleavage site, wherein the VDA is an anti-cancer and tubulin binding agent, and the MMP proteolytic cleavage site comprises an amino acid sequence - Arg-Ser-Cit-Gly-Hof-P2'-Leu- wherein P2' is an amino acid and is not tyrosine. The term "associated with" in the context of the invention is intended to include all direct and indirect means of association, generally covalent, including, but not limited to, chemical cross-linking or peptide bond linkage.

**[0009]** Compounds of the invention may be in the form of salts. In particular, the salts may be pharmaceutically acceptable salts. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., US, 1985, p. 1418, see also Stahl et al, Eds, "Handbook of Pharmaceutical Salts Properties Selection and Use", Verlag Helvetica Chimica Acta and Wiley-VCH, 2002.

**[0010]** The disclosure thus includes pharmaceutically-acceptable salts of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. For example the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g. from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl

chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

**[0011]** In a preferred aspect the invention provides a compound of formula (I)



wherein

X is a vascular disrupting agent (VDA);

Y is a peptide comprising a matrix metalloproteinase (MMP) proteolytic cleavage site; as defined in the claims.

**[0012]** Compounds according to the invention provide prodrugs which are converted to an active and potent VDA within the tumour environment by overexpressed MMPs. Tumour selective activation of a prodrug of the invention increases tumour levels, and decreases systemic levels, of the VDA and optionally additional active ingredients thereby greatly increasing their therapeutic index and efficacy.

**[0013]** VDAs comprise a multi-ring system, for example a fused or unfused bicyclic or tricyclic ring system. Thus X includes any multi-ring system of a VDA that is capable of binding to and disrupting tumour blood vessels.

**[0014]** VDAs can be divided into three classes:

1. (i) those compounds that interact with tubulin at the colchicine binding site on tubulin;
2. (ii) those compounds that share a common binding site on tubulin with the *Catharanthus* (Vinca) alkaloids;
3. (iii) compounds that promote the formation of stable microtubules in a manner similar to paclitaxel, a novel taxane diterpenoid isolated from the bark of the Pacific yew.

**[0015]** In a preferred aspect of the invention the VDA is a tubulin binding agent. The tubulin binding agent may be selected from the group consisting of i) those which interact with tubulin at the colchicine binding site: including but not limited to colchicine (including colchicine analogues such as N-acetylcolchinol-O- phosphate (ZD6126) and ABT-751), colchicinoids, combretastatins phenstatin, podophyllotoxins, steganacins, amphethinile and stilbenes; and ii) those which

interact with the Vinca binding site of tubulin: including but not limited to vincristine, vinblastine, vinflunine, maytansinoids, phomopson A, rhizoxin, auristatin (including analogues thereof) and dolastatin .

**[0016]** In a preferred aspect of the invention the VDA is a tubulin binding agent that interacts with the colchicine binding site within tubulin. In one embodiment of the invention the VDA is colchicine or an analogue/derivative thereof. Colchicine analogues or derivatives may include, but are not limited to, azademethylcolchicine, azacolchicine, N-methyl desacetylcolchicine, desacetylcolchicine.

**[0017]** In an embodiment of the invention the VDA is a non-peptide VDA. For example a VDA according to the invention may be a tubulin binding agent that is not auristatin or a derivative thereof.

**[0018]** Alternatively the VDA may be a tubulin binding agent selected from the group consisting of, but not limited to, combretastatins (e.g. combretastatin A-4 3-O-phosphate), auristatin (including analogues thereof), dolastatin; and flavenoids (e.g. tumour necrosis factor  $\alpha$  and 5,6-dimethylxanthenone-4-acetic acid (DMXAA), flavone acetic acid (FAA)). Thus in an alternative embodiment of the invention the VDA is a combretastatin.

**[0019]** Proteolytic cleavage at the MMP cleavage site by an MMP releases the VDA, and any other active agent associated with the MMP cleavage site, in active form.

**[0020]** The MMP family is divided into eight structural groups: five of which are secreted MMPs and three of which are membrane-type MMPs (MT-MMPs). MT-MMPs are localised on the cell surface.

**[0021]** In a preferred aspect of the invention the MMP is a membrane-type (MT-MMP). Thus the invention provides a compound of formula I wherein Y comprises a peptide sequence that is selectively cleaved by a MT-MMP.

**[0022]** MT-MMPs may be selected from the group consisting of

1. (i) type I transmembrane type MT-MMPs for example MMP-14 (MT1- MMP), MMP-15 (MT2-MMP), MMP-16 (MT3-MMP) and MMP-24 (MT5-MMP);
2. (ii) glycosyl phosphatidylinositol (GPI)-anchored structural group of MT-MMPs for example MMP-17 (MT4-MMP) and MMP-25 (MT6-MMP);
3. (iii) type II transmembrane class for example MMP-23.

**[0023]** The MMP cleavage site comprises a peptide sequence having an amide bond, typically a peptide bond, which is cleavable by a MMP. Preferably Y is a peptide sequence comprising between 7 and twenty amino acids. The amino acids may be D-amino acids or L-amino acids.

**[0024]** Preferably the MMP proteolytic cleavage site is a MT-MMP specific cleavage site such that cleavage between P1 and P1' selectively takes place by a MT-MMP for example MT-MMP14.

**[0025]** The MMP proteolytic cleavage site comprises the sequence:

P4-P3-P2-P1-P1'-P2'-P3'

wherein P1' to P3' and P1 to P4, are as defined in the claims and wherein proteolytic cleavage takes place between residues P1' and P1.

**[0026]** The disclosure provides an MMP cleavage site comprising a peptide sequence which is selectively cleaved by a MT-MMP. This disclosure provides a compound of formula (I) wherein Y comprises a peptide sequence in which P1' is a hydrophobic amino acid. As used herein, the term "hydrophobic" may refer to amino acids having a hydrophobicity that is greater than or equal to -1.10 and/or a net charge that is greater than or equal to 0 as described in Fauchere and Pliska Eur. J. Med Chem. 10:39 (1983). A hydrophobic or non-polar amino acid may also refer to an amino acid having a side chain that is uncharged at physiological pH, is not polar and that is generally repelled by aqueous solution. A hydrophobic amino acid may be selected from the group consisting of leucine, phenylalanine, proline, alanine, tryptophan, valine, isoleucine, methionine, tyrosine and threonine. P1' may be an amino acid with an aliphatic side chain. Alternatively P1' may be an amino acid with an aromatic side chain. P1' may also include non-natural hydrophobic amino acids and in an embodiment of the invention is homophenylalanine (Hof).

**[0027]** This disclosure provides a compound of formula (I) wherein Y comprises a peptide sequence in which P1 is a polar amino acid for example an amino acid selected from the group consisting of Asparagine (N), Serine (S) or Glycine (G). To improve selectivity for a MT-MMP at the cleavage site, generally P1 is not proline. Thus P1 is an amino acid excluding proline. In an embodiment of the invention, P1 is glycine.

**[0028]** This disclosure provides a compound of formula (I) wherein Y comprises a peptide sequence in which P2' is selected from the group consisting of polar, uncharged amino acids and/or basic amino acids including for example Arginine (R), Alanine (A), Leucine (L), Aspartic Acid (D), Threonine (T), Serine (S) and Proline (P). To improve selectivity for a MT-MMP at the cleavage site, P2' may be a methylated amino acid.

**[0029]** The present inventors have found that cleavage by non MT-MMPs, for example MMP2, takes place at both the P1'-P2' and P2'-P3' sites when P2' is tyrosine. Thus in an embodiment of the invention P2' is not tyrosine.

**[0030]** As used herein, the P3' residue may comprise any amino acid. In one embodiment of the invention P3' is Leucine (L). Where present, the P4' residue may comprise an amino acid with a nucleophilic side chain for example Lysine (L), Cysteine (C), Serine (S), Tyrosine (Y), Threonine (T), Glutamic acid (E), or Aspartic acid (D).

**[0031]** This disclosure provides a compound of formula (I) wherein Y comprises a peptide

sequence in which P2 is selected from the group consisting of acidic (for example glutamic acid), basic, hydrophobic or polar amino acids. P2 may also include non-natural hydrophobic amino acids for example citrulline (Cit). To improve selectivity for a MT-MMP at the cleavage site, it is preferred that P2 is not proline. Thus P2 is an amino acid excluding proline.

**[0032]** This disclosure provides a compound of formula (I) wherein Y comprises a peptide sequence in which P3 is a polar amino acid for example selected from the group consisting of Glycine (G), Alanine (A), Serine (S), Leucine (L), Isoleucine (I) and Threonine (T). It is preferred that P3 is not proline. In an embodiment of the invention P3 is serine.

**[0033]** This disclosure provides a compound of formula (I) wherein Y comprises a peptide sequence in which P4 is an amino acid containing a substantial side chain, for example an amino acid having a basic group in its side chain, including amino acids selected from the group consisting of Arginine (R) and Lysine (K). To improve selectivity for a MT-MMP at the cleavage site, it is preferred that P4 is arginine. Thus in an embodiment of the invention P4 is arginine.

**[0034]** The invention may provide a compound of formula (I) wherein the cleavage site, Y, comprises a sequence of amino acids in which one or more amino acids in the sequence are glycosylated to enhance hydrophilicity and as such solubility. Glycosylation of residues may be as follows:

0-glycosylation of amino acids in the sequence through the side-chains of serine, threonine, tyrosine;

N-glycosylation of amino acids in the sequence through the side-chains of aspartic acid, glutamic acid; and/or

S-glycosylation of amino acids in the sequence through cysteine.

**[0035]** The invention may provide a compound of formula (I) wherein the cleavage site, Y, comprises a sequence of amino acids in which one or more amino acids in the sequence are phosphorylated to enhance hydrophilicity and as such solubility. Suitable amino acids include Serine, Threonine, Tyrosine. In an embodiment of the invention there is provided a compound of formula (I) wherein Y comprises a peptide sequence in which P2', is phosphorylated. In a further embodiment of the invention there is provided a compound of formula (I) wherein Y comprises a peptide sequence in which P3, and optionally P2', is/are phosphorylated amino acids.

**[0036]** The invention also provides a compound of formula (I) wherein the cleavage site, Y, includes a peptide analogue, for example a peptide mimic, in which, by way of example an amide bond is replaced with olefinic bonds,  $\text{Na-}$  and/or  $\text{Ca-}$  methylated amino acids, unnatural amino acids and other approaches known in the art. Such peptidomimetic approaches are

used in the art to enhance the specificity of cleavage thereby serving to diminish undesired enzymatic hydrolysis. In an embodiment of the invention Y includes an analogue wherein one or more amide bonds within the amino acid sequence are replaced with Na- and/or Ca-methylated amino acids.

**[0037]** An embodiment of the invention comprises a compound of formula (I) wherein Y comprises a C-terminal site and an N-terminal site and wherein said C-terminal site is directly or indirectly linked to X and said N-terminal site is directly or indirectly linked to a further moiety for example c or Z as described hereinbelow.

**[0038]** An alternative embodiment of the invention comprises a compound of formula (I) wherein Y comprises a C-terminal site and an N-terminal site and wherein said N-terminal site is directly or indirectly linked to X and said C-terminal site is directly or indirectly linked to a further moiety for example c or Z as described hereinbelow.

**[0039]** In one preferred embodiment of the invention there is provided a compound of formula (I) wherein X is colchicine or an analogue thereof and Y is a peptide comprising the amino acid sequence as defined herein.

**[0040]** In a preferred aspect the invention provides a compound of formula (II)



wherein X and Y are as defined herein;

c is an end group or "capping group". Capping groups may be used to cap a peptide chain in pharmaceutical use in order to prevent non-specific degradation of the peptide for example by enzymes other than MMPs. c may include any appropriate moiety on the N- or C-terminus acting as a blocking group selected from the group including, but not limited to, aliphatics, aromatics, polycyclics, carbohydrates (e.g. simple sugars), amino acids (including D-amino acids). To improve solubility, c may be a hydrophilic group for example any of the aforementioned bearing additional polar functional groups (e.g. acids, amines, alcohols, phenols).

c may be represented by the formula  $(c)_n$  wherein n is an integer between 1 and 5. In an embodiment of the invention, c is represented  $(c)_n$  wherein c is an amino acid (e.g. a non-natural amino acid) and n is 3. In an embodiment of the invention c is not serine where n is 3. In a further embodiment c is not serine or quinic acid.

**[0041]** The present invention may further provide a "linker". The linker may be provided at the C and/or N terminus of Y. Preferably the linker is provided at the C terminus of Y. Preferably the linker is continuous with the amino acid sequence of Y. The linker may include any moiety that

is associated with Y and which may be removed chemically, enzymatically or decompose spontaneously. The linker may consist of a single amino acid (e.g. tyrosine) or may comprise an amino acid sequence. Where the linker comprises a sequence of amino acids, the sequence may provide a hydrophilic region that may facilitate cleavage by an MMP at Y. O-glycosylation of suitable amino acids in the sequence namely serine, threonine and tyrosine may enhance hydrophilicity and as such solubility.

**[0042]** Thus in a preferred aspect of the invention there is provided a compound of formula (III)



wherein X and Y are as defined herein; and

a is a linker wherein the linker is directly or indirectly associated with X.

**[0043]** In an embodiment the invention provides a compound of formula (IV)



wherein X, a, Y and c are as defined herein.

**[0044]** In a yet further preferred aspect of the invention there is provided a "spacer" which may be the same as, or different to, the linker described herein. The spacer may be provided at the C and/or N terminal of Y. Preferably the spacer is provided at the N terminus of Y and serves to prevent unwanted removal of c during synthesis. The spacer may be directly or indirectly associated with Y. The spacer may include any single amino acid (e.g.  $\beta$ -alanine), amino acid sequence, or a succinyl group. Thus the invention preferably provides a compound of formula (V)



wherein X, Y, and c are as defined herein;

b is a spacer as defined herein.

**[0045]** In a further embodiment the invention provides a compound of formula (VI)



wherein X, Y, a, b and c are as defined herein.

**[0046]** In one embodiment of the invention there is provided a compound of formula (VI) wherein X is colchicine (or an analogue thereof), Y is a peptide comprising the amino acid sequence as defined herein, a is tyrosine and b is alanine.

**[0047]** In a second aspect of the invention there is provided a compound, or pharmaceutically acceptable salt thereof, of formula (VII)



wherein X and Y are as defined herein; Z is an anti-cancer agent.

**[0048]** Preferably Z is an anticancer agent selected from the group consisting of a vascular disrupting agent, which may be the same as or different to X, an antimetabolite (e.g. 5-fluorouracil), a cytotoxic or anti-proliferative agent (e.g. anthracycline (e.g. doxorubicin), vinca alkaloid, taxane, cytotoxic nucleotide), a biotoxin, a radiotherapeutic, a hormonal agent or any natural products or agents known to induce a cytotoxic, cytostatic, anti-angiogenic or vascular disrupting effect.

**[0049]** In a preferred aspect of the invention there is provided a compound of formula (VIII)



wherein X, a, Y and Z are as defined herein.

**[0050]** In a yet preferred aspect of the invention there is provided a compound of formula (IX)



wherein X, a, Y, b and Z are as defined herein. In this aspect of the invention, the purpose of the spacer b is to convert the N-terminal amine of Y into a carboxylic acid to allow attachment of a compound Z wherein Z bears a free amine (for example where Z is doxorubicin). Where Z bears a free carboxylic acid, b is not required.

**[0051]** In a preferred aspect of the invention there is provided a compound of formula (VII) wherein X is colchicine or a derivative thereof for example azademethylcolchicine and Z is a cytotoxic agent for example doxorubicin. Preferably still Y is a peptide comprising the amino acid sequence as defined herein.

**[0052]** In a further preferred aspect of the invention there is provided a compound of formula (VII) wherein X and Z are selected from colchicine or an analogue or derivative thereof. Also provided is a compound of the invention wherein X and Z may both be colchicine. In this aspect, Y may be a peptide comprising the amino acid sequence as defined herein.

**[0053]** Compounds according to the invention may be prepared by solid-phase, for example attached to a polymeric support, or solution-phase synthesis for example in the presence of a coupling agent or using a convergent synthesis.

**[0054]** Also disclosed herein is a process for preparing a compound according to the invention the process comprising the steps of

- i) providing a solid support attached to X;
- ii) optionally attaching a linker a to the C or N terminal of X;
- iii) attaching amino acid residues step-wise to the C or N terminal of X, or the linker attached to X to provide the peptide sequence Y containing the MMP proteolytic cleavage sequence;
- iii) optionally attaching a capping group c to the respective C or N terminal of Y to provide a compound of formula (II) or (IV).

**[0055]** In a process the solid support is any polymeric support such as any polystyrene based or PEG based resin for example trityl-based resins. The linker may be a succinate or malonate derivative for example succinic anhydride.

**[0056]** A yet further process for preparing a compound according to the invention comprises the steps of

1. i) preparing peptide sequence Y;
2. ii) attaching a capping group c to the respective C or N terminal of Y;
3. iii) preparing a solution of X and the capped peptide prepared in (ii) in the presence of a coupling agent and Isolating the desired compound.

**[0057]** In a process Y is prepared by the step wise attachment of amino acids to a solid support to provide a peptide sequence. Alternatively, sequence Y may be synthesised in solution.

**[0058]** Any coupling agent known in the art may be used in a process of the invention for example EDAC, DCC, DIC, PyBOP, HCTU etc in a suitable solvent (e.g. DMF, THF etc).

**[0059]** In an alternative solution phase synthesis, one or more amino acids of the C-terminus of sequence Y may be conjugated to X in solution, to allow the remainder of the peptide sequence (e.g. pre-synthesised on a solid support as described previously) to be conjugated in solution in a convergent synthesis.

**[0060]** A process provides for the attachment of X to the C terminus of Y. Furthermore the

process may include the attachment of Z to the N-terminus of Y. For example the process may comprise the steps of:

1. i) Introduction of an amine group to X for attachment to the C terminus of Y; and optionally
2. ii) introduction of a carboxylic acid group (or isothiocyanate or isocyanate group) to Z for attachment to the N terminus of Y.

**[0061]** A further process provides for the attachment of X to the N-terminus of Y. Furthermore the process may include the attachment of Z to the C-terminus of Y. For example the process may comprise the steps:

1. i) introduction of a carboxylic acid group (or isothiocyanate or isocyanate group) to X for attachment to the N terminus of Y; and optionally
2. ii) introduction of a amine group to Z for attachment to the C terminus of Y.

**[0062]** In a process X is colchicine or an analogue or derivative thereof e.g. azademethylcolchicine and Z is a cytotoxic agent e.g. doxorubicin.

**[0063]** In a further aspect the invention provides the use of a MMP proteolytic cleavage site, in particular an MT-MMP specific cleavage site such as defined herein, in the site specific activation of a VDA. The term "site specific activation" as used herein means, in general terms and not limited to, the activation of a VDA by site specific cleavage at the MMP proteolytic cleavage site. Site specific cleavage at the proteolytic cleavage site is expected to take place concomitantly with the release and hence activation of the VDA.

### **Pharmaceutical Compositions and Uses**

**[0064]** In other aspects the invention provides a compound, or pharmaceutically acceptable salt thereof, as hereinbefore described for use in medicine. In further aspects, there is provided a pharmaceutical formulation comprising a compound as hereinbefore described. The formulation may contain at least one additional pharmaceutically acceptable component e.g. an excipient, diluent or carrier. Preferably the formulation is intended for parenteral administration.

**[0065]** The invention provides a pharmaceutical formulation comprising a compound according to the invention. In a preferred embodiment, the compound is of formula (VII).

**[0066]** In a preferred aspect of the invention said composition includes a pharmaceutically acceptable carrier or diluent.

**[0067]** The compositions of the invention are typically administered in effective amounts. An "effective amount" is that amount of a composition that alone, or together with further doses, produces the desired response. When administered, the pharmaceutical compositions of the present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers and optionally other therapeutic agents (for example, cisplatin; carboplatin; cyclophosphamide; melphalan; carmustine; methotrexate; 5-fluorouracil; cytarabine; mercaptopurine; daunorubicin; doxorubicin; epirubicin; vinblastine; vincristine; dactinomycin; mitomycin C; taxol; L-asparaginase; G-CSF; etoposide; colchicine; derferoxamine mesylate; and camptothecin).

**[0068]** The compositions of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. In the case of treating a particular disease, such as cancer, the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods known in the art.

**[0069]** Administration of the compositions to mammals other than humans, (e.g. for testing purposes or veterinary therapeutic purposes), is carried out under substantially the same conditions as described above. A subject, as used herein, is a mammal, preferably a human, and including a non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent.

**[0070]** When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients.

**[0071]** Pharmaceutical compositions may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.

**[0072]** The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt. The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal. Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as syrup, elixir or an emulsion.

**[0073]** Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of compound, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1, 3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

**[0074]** The compounds according to the invention may be used to treat a disease or condition associated with tissue over-expressing an MMP, in particular a MT-MMP. Thus the invention provides a method to treat cancer in a subject comprising administering an effective amount of a compound according to the invention. In a preferred method of the invention said subject is human.

**[0075]** As used herein, the term 'cancer' refers to cells possessing the capacity for autonomous growth i.e., an abnormal state or condition characterised by rapidly proliferating cell growth. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathological type or stage of invasiveness. The term 'cancer' includes malignancies of epithelial, endodermal and mesenchymal origin, particularly carcinomas and sarcomas, such as those affecting the respiratory system (mouth, nose, trachea, lung), gastrointestinal tract (tongue, esophagus, stomach, small intestines, colon, liver, pancreas, gall bladder, rectum), endocrine system (thyroid, pituitary, adrenal glands), genito-urinary tract (urinary bladder, kidney), reproductive system (breast, ovaries, uterus, cervix, prostate, penis, scrotum, testes), skin (melanocytes, epidermis, endodermis), nervous system (brain, spinal cord, glial cells, neurons) and lymphoid system.

**[0076]** The term 'carcinoma' is art recognised and refers to malignancies of epithelial origin including respiratory system carcinomas, gastrointestinal system carcinomas, endocrine system carcinomas, genito-urinary tract carcinomas, skin carcinomas, and carcinomas of the reproductive system. The term "carcinoma" also includes "adenocarcinomas" referring to carcinomas deriving from glandular tissue, "squamous carcinomas" referring to carcinomas of squamous origin, and "carcinosarcomas" referring to tumours composed of carcinomatous and sarcomatous tissue. Exemplary carcinomas include those forming from the epithelia of the cervix, prostate, breast, nose, head and neck, oral cavity, esophagus, stomach, liver, pancreas, colon, ovary, urinary bladder and lung, particularly non-small lung carcinoma.

**[0077]** The term 'sarcoma' is art recognised and refers to malignancies of soft tissues or

connective or supportive tissue, including bone, cartilage, adipose tissue, smooth muscle, skeletal muscle, nerve sheath, blood vessels, mesothelium, and gastrointestinal stroma. Further types of cancer include "leukaemias" which refer to tumours deriving from white blood cells, and "lymphomas" referring to tumours of the lymphoid system.

**[0078]** A pharmaceutical formulation comprising a compound according to the invention may be administered in combination, either sequentially or at a substantially similar time, as an anti-cancer agent (chemotherapeutic agent) including, but not limited to, an antimetabolite (e.g.5-fluorouracil), a cytotoxic or anti-proliferative agent (e.g.anthracycline, vinca alkaloid, taxane, cytotoxic nucleotide), a biotoxin, a radiotherapeutic, a hormonal agent or any natural products or agents known to induce a cytotoxic, cytostatic, anti-angiogenic or vascular disrupting effect.

**[0079]** As used herein, "treatment" refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and may be performed either for prophylaxis or during the course of clinical pathology.

**[0080]** In a further aspect the invention provides the use of a compound according to the invention in the manufacture of a medicament to treat cancer.

**[0081]** In one aspect of the present invention the compounds or compositions of the invention may be used to treat an inflammatory disorder and/or an inflammatory response. Thus, according to a further of the invention there is provided a method to treat an inflammatory disorder in a subject comprising administering an effective amount of a compound according to the invention.

**[0082]** The inflammatory disorder may be selected from the group consisting of atherosclerosis, rheumatoid arthritis, osteoarthritis, gout, lupus erythematosus, scleroderma, Sjorgen's syndrome, poly- and dermatomyositis, vasculitis, tendonitis, synovitis, bacterial endocarditis, periodontitis, osteomyelitis, psoriasis, pneumonia, fibrosing alveolitis, chronic bronchitis, bronchiectasis, emphysema, silicosis, pneumoconiosis, tuberculosis, ulcerative colitis, Crohn's disease, chronic inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, Guillan-Barre Syndrome and myasthenia gravis, mastitis, laminitis, laryngitis, chronic cholecystitis, Hashimoto's thyroiditis, and inflammatory breast disease. In one embodiment, the inflammatory disorder may be the result of tissue or organ rejection after transplantation. In particular embodiments the inflammatory disorder is selected from the group consisting of atherosclerosis, rheumatoid arthritis, osteoarthritis, sepsis and polyarthritis.

**[0083]** The compounds of the invention may be used to treat heart failure. Also provided is a use of a compound as described herein for the manufacture of a medicament to treat heart failure.

**[0084]** In one embodiment of the present invention the compounds of the invention may be useful in treating a wound (e.g. ulcers, lesions including cutaneous cuts or burns). Thus the

invention provides a method to treat a wound in a subject comprising administering an effective amount of a compound according to the invention. In a preferred method of the invention said subject is human.

**[0085]** The compounds of the invention may also be used to treat conditions and disorders associated with menstruation.

**[0086]** There is further provided a package or kit of parts comprising:

1. (1) a compound or composition described herein; together with
2. (2) instructions to use the compound in a method or use described herein.

**[0087]** The package defined herein may comprise more than one dosage unit in order to provide for repeat dosing. If more than one dosage unit is present, such units may be the same, or may be different in terms of the dose of the compound composition and/or physical form.

**[0088]** The extent of protection includes counterfeit or fraudulent products which contain or purport to contain a compound of the invention irrespective of whether they do in fact contain such a compound and irrespective of whether any such compound is contained in a therapeutically effective amount.

**[0089]** Included in the scope of protection are packages which include a description or instructions which indicate that the package contains a species or pharmaceutical formulation of the invention and a product which is or comprises, or purports to be or comprise, such a formulation or species. Such packages may be, but are not necessarily, counterfeit or fraudulent.

**[0090]** Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", means "including but not limited to", and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.

**[0091]** Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

**[0092]** Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.

**[0093]** The invention will now be described by way of example only with reference to the following Figures in which:

Figure 1 is a graph showing the metabolism of prodrug-1 versus time in tumour and non-tumour tissues *ex vivo*;

Figure 2 is a graph showing accumulation and levels of prodrug-1 in tumour-bearing mice following intraperitoneal administration;

Figure 3 is a graph demonstrating levels of VDA accumulating following intraperitoneal administration of prodrug-1 to tumour bearing mice;

Figure 4 is a graph showing differential metabolism of prodrug-2 in tumour homogenates expressing high MT1-MMP levels (HT1080) versus tumour homogenates expressing low MT1-MMP levels (MCF-7);

Figure 5 is a graph showing accumulation and levels of prodrug-2 in HT1080 tumour bearing mice following intraperitoneal administration;

Figure 6 is a graph demonstrating levels of VDA accumulating following intraperitoneal administration of prodrug-2 to HT1080 tumour bearing mice.

Figure 7: Relative mouse bodyweights during dose escalation study

Figure 8: Tumour growth during treatment with ICT-2522 (warhead)


Figure 9: Tumour growth during treatment with ICT-2588 (prodrug)

Figure 10: Tumour growth curves for mice treated with pro-drug (ICT-2588) compared with warhead (ICT-2552) administered at the molar equivalent dose a) ICT-2588, 37.5mg/kg & ICT-2552, 7.5mg/kg; b) ICT-2588, 50.0mg/kg & ICT-2552, 10.0mg/kg; c) ICT-2588, 62.5mg/kg & ICT-2552, 12.5mg/kg; and d) ICT-2588, 75.0mg/kg & ICT-2552, 15.0mg/kg;

Figure 11: Pro-drug, ICT-2588, showing modifications including phosphorylated amino acid residues, end-cap, warhead and P2' alternatives;

Figure 12: A graph demonstrating the stability of ICT 3053 (P2' = Ala) in both tumour (HT1080) and liver (murine) homogenates. This is an example of the data obtained for this series of molecules and a summary of the data is given in table 1; and

Figure 13: Stability data for molecules with phosphate attached to serine (ICT3047) tyrosine (ICT 3048) and both serine and tyrosine (ICT3028). Data show percent of parent molecule remaining following incubations in tumour (HT1080, closed symbols) and murine liver (open symbols) homogenate for the indicated time. This is representative data from multiple experiments. Chromatographic separations were established to monitor the dephosphorylation of each molecule.

**Materials and Methods****EXAMPLE 1****Synthesis of immobilised colchicine derivative, azademethylcolchicine****[0094]****Synthesis of 1:**

**[0095]** Ammonia solution (35%, 15 mL) was added to colchicine (750 mg, 1.88 mmol, 1.00 eq) and the reaction mixture stirred at room temperature overnight. The crude product was washed with KHSO<sub>4</sub> (1M, aq), dried with MgSO<sub>4</sub>, filtered and concentrated under reduced pressure. It was subsequently purified by flash chromatography on silica gel (gradient elution: CH<sub>2</sub>Cl<sub>2</sub>/methanol 95:5 to 10:1) to give 1 as a yellow solid (427 mg, 1.11 mmol, 59%).

$\delta$ <sub>H</sub> (600 MHz, CDCl<sub>3</sub>), 7.99 (1 H, broad s, NH), 7.56 (1 H, d, J 2.1, C8-H), 7.32 (1H, d, J 10.7, C11-H), 6.88 (1 H, d, J 11.0, C10-H), 6.52 (1 H, s, C4-H), 6.03 (2 H, broad s, NH<sub>2</sub>), 4.68 (1 H, ddd, J 12.6, 6.5 and 6.5, C7-H), 3.93 (3 H, s, OCH<sub>3</sub>), 3.88 (3 H, s, OCH<sub>3</sub>), 3.60 (3 H, s, OCH<sub>3</sub>), 2.47 (1 H, dd, J 13.4 and 6.2, C5-CH<sub>2</sub>), 2.35 (1 H, ddd, J 13.4, 12.7 and 6.9, C5-CH<sub>2</sub>), 2.29-2.23 (1 H, m, C6-CH<sub>2</sub>), 1.98 (3 H, s, CH<sub>3</sub>), 1.90-1.88 (1 H, m, C6-CH<sub>2</sub>); ES m/z (%) 385 [M<sup>+</sup>+H] (100).

**Synthesis of 2:**

**[0096]** HCTU (642 mg, 1.55 mmol, 1.50 eq) and diisopropylethylamine (DiPEA, 516  $\mu$ L, 404 mg, 3.11 mmol, 3.00 eq) were added to a solution of Fmoc-tyr(*t*Bu)-OH (714 mg, 1.55 mmol, 1.50 eq) in DMF (10 mL). After stirring at room temperature for 5 minutes, 1 (398 mg, 1.04 mmol, 1.00 eq) was added to the solution. The reaction mixture was stirred at 50°C for 22h. DMF was removed *in vacuo* and the resultant oil was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The organic phase was washed with KHSO<sub>4</sub> (aq, 2 x 20 mL), dried with MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by flash chromatography (gradient elution: CH<sub>2</sub>Cl<sub>2</sub>/methanol 100:0 to 99:1 to 98:2) to give **2** as a yellow solid (530 mg, 642  $\mu$ mol, 67%).

$\delta$ <sub>H</sub> (600 MHz, CDCl<sub>3</sub>), 10.42 (1 H, broad s, NH), 9.02 (1 H, d J 10.7, C11-H), 7.75 (2 H, d, J 7.2, C23-H, C24-H), 7.54 (2 H, d, J 7.2, C20-H, C27-H), 7.45 (1 H, d, J 11.0, C10-H), 7.39 (2 H, dd, J 7.2 and 7.2, C22-H, C25-H), 7.29 (2 H, dd, J 6.6 and 6.6, C21-H, C26-H), 7.19 (1 H, broad s, C8-H), 7.03 (2 H, d, J 7.9, C14-H, C17-H), 6.81 (2 H, d, J 7.9, C15-H, C16-H), 6.50 (1 H, s, C4-H), 5.88 (1 H, broad s, NH), 5.25 (1 H, broad s, C12-H), 4.73-4.67 (1 H, m, C7-H), 4.43 (1 H, dd, J 10.0 and 7.6, C18-CH<sub>2</sub>), 4.28 (1 H, dd, J 10.0 and 7.2, C18-CH<sub>2</sub>), 4.16 (1 H, dd, J 7.2 and 6.19, C19-H), 3.93 (3 H, s, OCH<sub>3</sub>), 3.88 (3 H, s, OCH<sub>3</sub>), 3.62 (3 H, s, OCH<sub>3</sub>), 3.21 (1 H, dd, J 13.1 and 4.8, C13-CH<sub>2</sub>), 3.11 (1 H, dd, J 13.1 and 5.5, C13-CH<sub>2</sub>), 2.53 (1 H, dd, J 13.4 and 6.2, C5-CH<sub>2</sub>), 2.40 (1 H, ddd, J 13.4, 12.7 and 6.9, C5-CH<sub>2</sub>), 2.22-2.15 (1 H, m, C6-CH<sub>2</sub>), 1.88 (3 H, s, CH<sub>3</sub>), 1.80 (1 H, ddd, J 11.5, 11.3 and 6.9, C6-CH<sub>2</sub>), 1.22 (9 H, s, C(CH<sub>3</sub>)<sub>3</sub>); ES m/z (%) 826 [M<sup>+</sup>] (100).

#### Synthesis of **3**:

**[0097]** TFA (2 mL) was added to a solution of **2** (486 mg, 589  $\mu$ mol, 1.00 eq) and the reaction mixture stirred for 20 min. TLC indicated quantitative conversion to the product. The product was concentrated under reduced pressure, with toluene coevaporation to give **3** in quantitative yield.


$\delta$ <sub>H</sub> (600 MHz, CDCl<sub>3</sub>), 10.08 (1 H, broad s, NH), 8.99 (1 H, d J 10.7, C11-H), 7.71 (2 H, d, J 6.2, C23-H, C24-H), 7.55 (1 H, s, C8-H), 7.49 (2 H, dd, J 6.5 and 6.5, C20-H, C27-H), 7.41 (1 H, d, J 10.2, C10-H), 7.33 (2 H, dd, J 6.2 and 6.2, C22-H, C25-H), 7.26-7.21 (2 H, m, C21-H, C26-H), 6.91 (2 H, d, J 8.3, C14-H, C17-H), 6.56 (2 H, d, J 7.2, C15-H, C16-H), 6.45 (1 H, s, C4-H), 5.93 (1 H, broad s, NH), 5.28 (1 H, s, NH), 4.95-4.90 (1 H, m, C12-H), 4.60 (1 H, ddd, J 11.7, 5.8 and 6.9, C7-H), 4.39 (1 H, dd, J 8.9 and 8.6, C18-CH<sub>2</sub>), 4.29-4.24 (1 H, m, C18-CH<sub>2</sub>), 4.12 (1 H, dd, J 6.9 and 6.9, C19-H), 3.90 (3 H, s, OCH<sub>3</sub>), 3.84 (3 H, s, OCH<sub>3</sub>), 3.54 (3 H, s, OCH<sub>3</sub>), 3.08 (2 H, d, J 5.2, C13-CH<sub>2</sub>), 2.44 (1 H, dd, J 13.4 and 6.2, C5-CH<sub>2</sub>), 2.33-2.26 (1 H, m, C5-CH<sub>2</sub>), 2.15-2.09 (1 H, m, C6-CH<sub>2</sub>), 1.82 (3 H, s, CH<sub>3</sub>), 1.75-1.69 (1 H, m, C6-CH<sub>2</sub>); ES m/z (%) 770 [M<sup>+</sup>] (100).

#### Preparation of **4**:

**[0098]** 2-Chlorotriyl chloride resin (Novabiochem, 100-200 mesh, substitution 1.4 mmolg<sup>-1</sup>, 589 mg, 0.765 mmol, 1.00 eq) was suspended in a solution of **3** (589 mg, 0.765 mmol, 1.00 eq), dimethylaminopyridine (10 mg, 76.5 µmol, 0.01 eq), DiPEA (247 mg, 1.913 mmol, 333 µL, 2.50 eq) and pyridine (241 mg, 3.061 mmol, 248 µL, 4.00 eq) in THF (10 mL) and stirred for 6 hours at 50°C. The resin was subsequently filtered and washed thoroughly with THF. The resin was then capped by washing the resin carefully with methanol (CH<sub>2</sub>Cl<sub>2</sub>:MeOH:DiPEA 17:2:1, 100 mL). Resin **4** was dried overnight over P<sub>2</sub>O<sub>5</sub>. Dry resin weight: 593 mg (loading 56%).

#### General procedure for synthesis of endopeptidase-activated pro-drugs

**[0099]**



**5** fluo-bala-glu-pro-cit-gly-hof-tyr-leu-tyr-colch

**[0100]** As an example, peptide conjugate **5** was synthesised using conventional solid phase peptide synthesis, from immobilised colchicine derivative **4**, using an Fmoc-based strategy.


**[0101]** *Na*-Fmoc strategy synthesis was achieved manually using 2-hlorotriylderivatised resin. The resin was swelled thoroughly in DMF, followed by removal of the *N*Fmoc protecting group by treatment with 20% v/v piperidine in DMF (3 x 3 min). All couplings were performed in DMF, employing 2.5-fold molar excesses of *Na*-Fmoc protected amino acids (with appropriate side-chain protecting groups), and activated using HCTU/HOBt/DiPEA. *Na*-Fmoc deprotections were performed using 20% piperidine in DMF (3 x 3 min). The success of couplings and deprotections was monitored using the ninhydrinbased Kaiser test. Unsuccessful couplings were repeated. After the final *Na*-Fmoc deprotection, the peptide chain was endcapped with fluorescein isothiocyanate (2.50 eq, in the presence of DiPEA, 1.50 eq). The success of this reaction was also monitored by the Kaiser test.

**[0102]** An additional  $\beta$ -alanine residue was incorporated into the sequence to overcome incompatability of the thiourea linkage and the acidic conditions of cleavage (the thiourea can rearrange, and the carbonyl carbon of the preceding amide bond can undergo nucleophilic attack by the sulphydryl-like function so formed. This leads to cleavage of the amide bond, with concomitant formation of a cyclic thiazolinone. The thiazolinone can undergo rearrangement in the presence of aqueous acid to form a thiohydantoin).


**[0103]** On completion of the sequence, the resin was washed (DMF, CH<sub>2</sub>Cl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH) and dried *in vacuo* over KOH to constant weight. Peptides were cleaved from the resin by mild acidolysis using TFA-H<sub>2</sub>O-triisopropylsilane 95:2.5:2.5 for 2 h at RT, with simultaneous sidechain de-protection. Following cleavage, the TFA was removed under reduced pressure. The crude product was extracted into 95% aqueous acetic acid and lyophilised. Crude peptide was subsequently analysed using reversed phase HPLC and purified using preparative HPLC (purity >97%). Pure fractions were combined and lyophilised. A C18 preparative column (Zorbax Eclipse, 21.2 x 150mm XDB-C18, Agilent) was used for peptide conjugate purification. Mobile phases were as follows; Mobile Phase A: HPLC grade water and 0.045% TFA. Mobile Phase B consisted of 10% HPLC grade water, 90% acetonitrile and 0.045% TFA. Mobile phase was degassed by vacuum filtration through a 0.45μm pore cellulose nitrate filter (Sartolon, Sartorius, UK). Chromatography was performed at room temperature and the flow rate maintained at 21.2 ml/min. Mobile phase gradients were optimised and scaled up from a gradient previously designed in-house for structurally similar compounds. UV absorbance detection was optimal at 255 nm. ES m/z (%) 951.8 [M+H]<sup>2+</sup> (100). RP-HPLC (Gradient: 0 min 30% B; 5 min 35% B; 25 min 80% B; 26 min 100% B; 27 min 100% B; 30 min 30% B) Rt = 11.98 min.


**Attachment of colchicine to a peptide sequence through its B-ring to the peptide *N*-terminus**

**[0104]** To enable attachment of a colchicine moiety through the peptide *N*-terminus, the following strategy will be used. The B-ring amine can be de-masked using published methods. Acylation with aspartic acid will introduce a carboxylic acid to the molecule (from the amino acid side chain) thereby enabling conjugation to the free amine at the peptide *N*-terminus (see below).




**[0105]** Acetylation of the amide bond will also be examined, to assess whether parent colchicine is released following MMP activation and subsequent exopeptidase degradation.





**Attachment of colchicine analogue to a peptide sequence through its C-ring to the peptide N-terminus**

**[0106]** To enable attachment of a colchicine analogue through its *N*-terminus, the following strategy will be used. Acylation of azademethylcolchicine can be effected as described previously. On de-masking of the Boc-protecting group, acylation with succinic anhydride (or a mono-protected succinate or malonate (or similar) derivative) follows. Deprotection will then afford a carboxylic acid functionality suitable for attachment to the peptide *N*-terminus.




**Strategies for the attachment of doxorubicin to a peptide sequence:**

**1) N-terminal doxorubicin linkage**


**[0107]** To enable attachment of doxorubicin through the peptide *N*-terminus (following peptide synthesis using the immobilised colchicine derivatised resin previously described) it must first be modified to introduce a carboxylic acid. Examples include reaction with succinic anhydride (strategy 1, below). However, by utilising the side chain of aspartic acid (both natural amino acids), as shown below (strategy 2) a natural amino acid (as opposed to a foreign chemical entity) is released on metabolism:

**Strategy 1: (succinyl spacer)**


[0108]


**Strategy 2: (amino acid spacer)**

[0109]

**Strategy 3**

[0110] In a manner analogous to that described in Strategies 1 and 2 the doxorubicin sugar amine can be acylated by an amino acid, which on de-protection can be further derivatised by a succinate (or otherwise) spacer to yield a derivative which can be attached to the peptide *N*-terminus.






## 2) C-terminal doxorubicin linkage


**[0111]** Protection of the amine group of doxorubicin with Dde (a commonly used protecting group in peptide chemistry and by our group) would allow immobilisation of the agent onto a trityl-based (or otherwise) resin. Subsequent removal of the Dde group would de-mask the amine, allowing a peptide sequence to be constructed from this point (i.e. through the C-terminus). Standard Fmoc-based solid phase synthesis would produce a peptide sequence.

**[0112]** An appropriately derivatised VDA could then be conjugated through the N-terminus. Resin cleavage and purification would be as previously described.



## Incorporation of glycosylated amino acids

**[0113]** Amino acids with appropriate side chain functionality (e.g. serine, tyrosine, threonine) can be glycosylated (with mono-, di- or trisaccharides) to produce peptides with enhanced aqueous solubility. Such a carbohydrate-derivatised moiety could be used in place of serine, for example (see scheme below).




## Results

### 1) MMP-activated prodrug - pan MMP targeted

#### Structure:

[0114]



Fluorescein-[Ala]-[Glu]-[Pro]-[Cit]-[Gly]-[Hof]-[Tyr]-[Leu]-[Tyr]-VDA2  
(Hof = homophenylalanine; Cit = citrulline; VDA-2 = azademethylcolchicine)

1. a) Prodrug-1 has been screened using normal mouse plasma, normal mouse liver homogenate and experimental human tumour model homogenate (HT1080 xenograft; known to express majority of MMPs) *ex vivo*. Prodrug cleavage and metabolism were detected using LC/MS/MS.
  1. a. Prodrug-1 was stable in plasma and liver, supporting systemic stability of these therapeutics (Figure 1).
  2. b. Prodrug-1 was metabolised in tumour homogenate, supporting activation of these therapeutics in tumours expressing MMPs (Figure 1).
2. b) Prodrug-1 is cleaved rapidly at the Glycine-Homophenylalanine (Gly-Hof) by recombinant MMP-2, MMP-9, MMP-10 and MMP-14 at least. Demonstrated by LC/MS/MS and mass spectrometry (data not shown)
3. c) Prodrug-1 was administered *in vivo* via the intraperitoneal route to mice bearing subcutaneous HT1080 tumour model (expression of majority of MMPs). Plasma, tissues and tumours were collected at regular intervals post-dosing. Levels of prodrug and VDA2 were assessed by LC/MS/MS.
  1. a. Prodrug-1 accumulated and was detected in all tissues analysed (Figure 2).
  2. b. Highest prodrug-1 levels were observed in the tumour (Figure 2).
  3. c. Prodrug-1 not detectable after 24 hours post-dosing. (Figure 2)
  4. d. VDA2 was detectable at low levels in normal tissues following prodrug-1 administration (Figure 3)
  5. e. VDA2 levels were detected at high levels in tumour tissue following prodrug-1 administration (Figure 3)


6. f. VDA2 was still detectable at high levels in tumour and was undetectable in normal tissues after 24 hours post-dosing with prodrug-1 (Figure 3)

## 2) MMP-activated prodrug (ICT-2588)

-targeted to Membrane-type MMPs (MT-MMPs)

**Structure:**

**[0115]**



Fluorescein - **Ala** - **Arg** - **Ser** - **Cit** - **Gly** - **Hof** - **Tyr** - **Leu** - **Tyr** - VDA2

d) Compound 1 was modified in order to change the MMP-targeting of the compound from being pan-MMP to MT-MMP selective (Prodrug-2)

1. a. Arginine was incorporated in place of the Glutamic acid at the P4 position
2. b. Proline was removed and replaced with Serine at the P3 position

e) Prodrug-2 has been screened using normal mouse plasma, normal mouse liver homogenate and experimental human tumour model homogenates demonstrating high MT1-MMP (MMP-14) expression and activity (HT1080) and low MT1-MMP expression and activity (MCF-7) *ex vivo*. Prodrug-2 cleavage and metabolism were detected using LC/MS/MS.

1. a. Prodrug-2 remained intact in plasma supporting systemic stability of this therapeutic.
2. b. Prodrug-2 remained stable in murine liver homogenates
3. c. Prodrug-2 was metabolised rapidly in tumour homogenate expressing high MT-MMP levels (HT1080) relative to tumour homogenate expressing low MT-MMP levels (MCF7) (Figure 4).
4. d. These data support the systemic stability of this prodrug and the selectivity of activation by MT-MMPs.

f) Prodrug-2 is cleaved differentially by MMPs as shown by LC/MS/MS and mass spectrometry (data not shown):

1. a. Cleaved rapidly at the Glycine-Homophenylalanine (Gly-Hof) by recombinant MMP-

14.


2. b. Cleaved slowly at the Homophenylalanine-Tyrosine (Hof-Tyr) by recombinant MMP-2. Demonstrating different cleavage to that observed with prodrug-1.
3. c. Prodrug-2 is not cleaved by recombinant MMP-9, in contrast to prodrug-1
4. d. These data support the MMP selective cleavage of prodrug-2

g) Prodrug-2 was administered *in vivo* via the intraperitoneal route to mice bearing subcutaneous HT1080 tumour model (MT1-MMP positive). Plasma, tissues and tumours were collected at regular intervals post-dosing. Levels of prodrug-2 and VDA2 were assessed by LC/MS/MS.


1. a. Prodrug-2 accumulated and was detected in all tissues analysed (Figure 5).
2. b. Highest prodrug-2 levels were observed in the tumour (Figure 5).
3. c. Liver was representative of all normal tissues analysed. (Figure 5)
4. d. VDA2 was undetectable in plasma following administration of prodrug-2 (Figure 6)
5. e. High concentrations of VDA2 were detected in tumour following prodrug-2 administration (Figure 6)
6. f. Levels of VDA2 in tumour were 10 times higher than that detected in normal tissues following administration of prodrug-2 (Figure 6)
7. g. High levels of prodrug-2 and VDA2 were still detectable in tumour 48 hours post administration.

3. Synthesised conjugates (based on MT-MMP prodrug) which have proved unsuccessful. Prodrugs including the following endcaps were insufficiently stable in plasma and/or liver

1. (1) 3 x D-Serine
2. (2) quinic acid + 2 x D-Serine



NH<sub>2</sub>-D-Ser-D-Ser-D-Ser-Arg-Ser-Cit-Gly-HoPhe-Tyr-Leu-Tyr-Warhead



Quinic-D-Ser-D-Ser-Arg-Ser-Cit-Gly-HoPhe-Tyr-Leu-Tyr-Warhead

## EXAMPLE 2

## Dose Response Antitumour Study

### Materials and Methods

#### **Synthesis of ICT-2588 - see Example 1**

**[0116] Synthesis of ICT-2552:** Ammonia solution (35%, 15 mL) was added to colchicine (750 mg, 1.88 mmol, 1.00 eq) and the reaction mixture stirred at room temperature overnight. The crude product was washed with KHSO4 (1M, aq), dried with MgSO4, filtered and concentrated under reduced pressure. It was subsequently purified by flash chromatography on silica gel (gradient elution: CH2Cl2/methanol 95:5 to 10:1) to give **ICT-2552** as a yellow solid (427 mg, 1.11 mmol, 59%).  $\delta$ H (600 MHz, CDCl3), 7.99 (1 H, broad s, NH), 7.56 (1 H, d, J 2.1, C8-H), 7.32 (1H, d, J 10.7, C11-H), 6.88 (1 H, d, J 11.0, C10-H), 6.52 (1 H, s, C4-H), 6.03 (2 H, broad s, NH2), 4.68 (1 H, ddd, J 12.6, 6.5 and 6.5, C7-H), 3.93 (3 H, s, OCH3), 3.88 (3 H, s, OCH3), 3.60 (3 H, s, OCH3), 2.47 (1 H, dd, J 13.4 and 6.2, C5-CH2), 2.35 (1 H, ddd, J 13.4, 12.7 and 6.9, C5-CH2), 2.29-2.23 (1 H, m, C6-CH2), 1.98 (3 H, s, CH3), 1.90-1.88 (1 H, m, C6-CH2); ES m/z (%) 385 [M+H]<sup>+</sup> (100).

**[0117]** ICT-2552 and ICT-2588 ('prodrug') were administered as a single dose via the intraperitoneal route to Balb/C mice bearing subcutaneous HT1080 xenografts. Each of the nine dosing groups comprised 8 mice. The anti-tumour effects of the compounds were assessed by determination of tumour volume and the existence of off-target toxicity was ascertained via monitoring mouse body weight.

The dosing groups evaluated ICT-2588 (prodrug) relative to the molar equivalent dose of ICT-2552 (warhead), and were:

- 10% DMSO/oil (solvent control)
- ICT-2588 at 37.5 mg/kg; 50.0 mg/kg; 62.5 mg/kg; 75.0 mg/kg
- ICT-2552 at 7.5 mg/kg; 10.0 mg/kg; 12.5 mg/kg; 15 mg/kg

### Results

**[0118]** No significant loss in body weight was observed throughout the study (Fig. 7)

**[0119]** The weight of all mice was within the tolerated loss of 15% of bodyweight, therefore the

compounds are not classified as toxic to the whole body system.

### EXAMPLE 3

#### Tumour response study

#### Results

**[0120]** The results of the study are shown in Figures 8 to 10 and in the following Tables. Tumour responses were observed at all tested dose levels of ICT-2522 and ICT-2588.

Table 1: Antitumour efficacy of compounds relative to untreated control group

Compound	Dose (mg/kg)	Mean time to RTV2 (days)	Median time RTV2 (days)	Growth delay (days)	Significance <sup>a</sup>	Maximum % weight loss (day) <sup>b</sup>
Control	-	2.3	2.2	-	-	5 (6)
ICT-2588	37.5	4.4	4.2	2.0	p<0.01	3 (3)
ICT-2588	50.0	5.5	6.0	3.8	p<0.01	5 (3)
ICT-2588	62.5 <sup>c</sup>	7.7	7.8	5.6	p<0.01	4 (3)
ICT-2588	75.0	6.8	6.6	4.4	p<0.01	5 (3)
ICT-2552	7.5	4.0	3.8	1.6	p<0.01	3(4)
ICT-2552	10.0	4.4	4.2	2.0	p<0.01	6 (6)
ICT-2552	12.5	4.5	4.7	2.5	p<0.01	6 (1)
ICT-2552	15.0	4.1	4.1	1.9	p<0.01	5 (1)

<sup>a</sup>Statistics worked out based on the time it takes the tumour to double in size from day 0.

<sup>b</sup>Maximum weight loss well within the accepted levels of 15%.

<sup>c</sup>One animal showed complete tumour remission (final measurement day 21)

**[0121]** A significant delay in tumour growth was observed at all evaluated doses of ICT-2552 (warhead) and ICT-2588 (prodrug).

**[0122]** A relationship between dose of compound and degree of tumour growth delay was observed with both compounds. The effects being greater with ICT-2588 (prodrug) .

**[0123]** One animal demonstrated complete tumour remission with ICT-2588 at a dose of 62.5

mg/kg .

Table 2: Comparison of antitumour efficacy between dose of ICT-2588 (prodrug) and ICT-2552 (warhead) administered at the molar equivalent dose

Dose of ICT-2588 (mg/kg)	Dose of ICT-2552 (mg/kg)	Growth delay with prodrug (Days)	Growth delay with warhead (Days)	Significance of differential between equimolar doses of ICT-2588 and ICT-2552 <sup>a</sup>
37.5	7.5	2.0	1.6	p>0.05
50.0	10.0	3.8	2.0	p<0.05
62.5 <sup>c</sup>	12.5	5.6	2.5	p<0.05
75.0	15.0	4.4	1.9	p<0.01

<sup>a</sup>Statistics worked out based on the time it takes the tumour to double in size from day 0.

<sup>c</sup>One animal showed complete tumour remission (final measurement day 21) ICT-2588 (prodrug) induced a significantly greater antitumour response than ICT-2522 (warhead) when administered at equimolar doses .

#### EXAMPLE 4

#### **Modifications to ICT-2588**

##### **i) Improvement of prodrug solubility through introduction of phosphorylated amino acid side chains**

**[0124]** To increase prodrug solubility, phosphorylated amino acid side chains are introduced into the peptide sequence of ICT-2588 (hydrolysable by plasma phosphatases). Phosphate-derivatised amino acids are commercially available, as benzyl-protected moieties, and are incorporated into peptides using our synthetic methodology. We are synthesising and evaluating phosphorylation modification of two sites within the peptide sequence; P2' (Tyr), P3 (Ser), and both P2' and P3 (see Fig. 11). In addition, we are addressing the effect of phosphorylation of P2' (Tyr) upon prodrug activation by MT-MMPs (cleave at P1-P1') and MMP-2 (cleave at P1'-P2') to address the potential for further increasing MMP selectivity.

##### **ii) Improvement of solubility via modification of prodrug endcapping group**

**[0125]** We are exploring the replacement of the fluorescein group with a more hydrophilic


group (see figure 11) as alternative prodrugs with improved solubility. Our objective is to improve prodrug solubility whilst retaining MT-MMP selectivity, tumour selective activation and antitumour activity. Prodrugs incorporating these alternative endcaps to ICT2588 are being assessed in terms of compound solubility relative to parent prodrug *in vitro*, prodrug stability and activation in the HT1080 tumour model, mouse plasma and liver homogenate *ex vivo*, and retention and potential improvement of MT-MMP selectivity.

### iii) Modification of P2' site within prodrug

**[0126]** The effects of modification of the P2' site (Tyr) of the prodrug with reference to tissue stability, tumour cleavage and MMP activation *ex vivo* are being assessed. The focus is on the P2' site of the prodrug as we have demonstrated cleavage by other non-MT-MMPs at both the P1'-P2' and P2'-P3' sites. We are using prodrug variants incorporating the main types of amino acid side chain (Ala, Asp, Asn, Leu, Ser, Pro).


### iv) Development of Dual-headed prodrug incorporating doxorubicin

**[0127]** Following treatment with ICT2588 a thin viable rim of tumour cells was observed at the tumour periphery. Current understanding of tumour vascularisation indicates that the viable rim is maintained by the vasculature of the immediately surrounding normal tissues. A consequence of this is that administration of a VDA-releasing prodrug in combination with standard chemotherapy should increase further the antitumour effect observed. We are developing a dual-headed prodrug containing our azademethylcolchicine warhead (ICT2552) and a doxorubicin warhead (replacing the endcap) (see below). We are evaluating this dual-headed prodrug in terms of prodrug stability and activation in the HT1080 tumour model, mouse plasma and liver homogenate *ex vivo*.



**[0128]** Derivatisation at the amine is required since attachment to the peptide will be through the *N*-terminus. Current strategy is to acylate with succinic anhydride, yielding a succinate derivative bearing a free carboxylic acid which can be linked to the peptide via an amide bond.

Alternative strategy to be evaluated is to use the side chain of aspartic acid with alkyl/aryl blocking group R.



**[0129]** Table 3 is a summary of stability data for a series of molecules with changes in the P2' position. Half lives are the mean taken from four independent experiments. Liver represent murine liver homogenate and tumour represents HT1080

	P2'AA	Liver	Tumour
		t1/2 (min)	t1/2 (min)
ICT2588	Tyr	149	33
ICT3055	Asp	67	7
ICT3053	Ala	76	17
ICT3054	Ser	66	9
ICT3078	Asn	76	11
ICT3097	Pro	110	24
ICT3080	Leu	134	48

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Non-patent literature cited in the description

- **DENEKAMP**, JBr J Cancer, 1982, vol. 45, 136-139 [\[0003\]](#)
- **TOZER et al.** Nat Rev Cancer, 2005, vol. 5, 423-435 [\[0003\]](#) [\[0005\]](#) [\[0005\]](#)
- **LIPPERT** JWBioorg Med Chem, 2007, vol. 15, 605-615 [\[0003\]](#)
- **CHAUDRI et al.** J Mol Biol, 2000, vol. 303, 679-692 [\[0005\]](#)
- **QUINN et al.** J Med Chem, 1981, vol. 24, 636-639 [\[0005\]](#)
- Remington's Pharmaceutical SciencesMack Publishing Company198500001418- [\[0009\]](#)
- Handbook of Pharmaceutical Salts Properties Selection and UseVerlag Helvetica Chimica Acta and Wiley-VCH20020000 [\[0009\]](#)
- **FAUCHEREPLISKA** Eur. J. Med Chem., 1983, vol. 10, 39- [\[0026\]](#)
- Remington's Pharmaceutical SciencesMack Publishing Co. [\[0073\]](#)

**Patentkrav**

- 1. Forbindelse eller farmaceutisk acceptabelt salt deraf der omfatter et vaskulært ødelæggende middel (VDA), som er associeret med et peptid, der omfatter et proteolytisk spaltningssted for matrixmetalloproteinase (MMP), hvilket VDA er et anti-cancer- og tubulinbindingsmiddel og hvilket proteolytiske spaltningsted for MMP omfatter en aminosyresekvens -Arg-Ser-Cit-Gly-Hof-P2'-Leu-, hvor P2' er en aminosyre og ikke er tyrosin.**
- 10 2. Forbindelsen ifølge krav 1, hvilken forbindelse har formlen (I)**
$$X-Y \quad (I)$$

hvor

X er VDA; og

Y er peptidet, der omfatter et proteolytisk spaltningssted for MMP.
- 15 3. Forbindelse ifølge krav 1 eller 2, hvor VDA vekselvirker med tubulin på colchicinbindingsstedet på tubulin og er valgt blandt azademethylcolchicin, colchicin, azacolchicin, N-methyl-deacetylcolchicin, deacetylcolchicin, N-acetylcolchicinol-O-phosphat, colchicinoider, combrestatiner, phenstatin, podophyllotoxiner, steganaciner, amfetinyler, stilbener eller flavonoider, eventuelt hvor VDA er valgt blandt azademethylcolchicin, colchicin, azacolchicin, N-methyl-deacetylcolchicin, deacetylcolchicin og fortrinsvis hvor VDA er azademethylcolchicin.**
- 25 4. Forbindelse ifølge krav 1 eller 2, hvor VDA deler et fælles bindingssted på tubulin med catharanthus (Vinca)-alkaloiderne, eventuelt hvor VDA er valgt blandt vincristin, vinblastin, vinflunin, maytansinoider, phomopsin A, rhizoxin, auristatin, auristatin-analog eller dolastatin.**
- 30 5. Forbindelse ifølge krav 1 eller 2, hvor VDA fremmer dannelsen af stabile mikrotubuli på en måde svarende til paclitaxel.**

6. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor det proteolytiske spaltningsssted for MMP er en peptidsekvens mellem 7 og 10 aminosyrer.

5 7. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor P2' er valgt fra

- polære, uændrede aminosyrer og/eller basiske aminosyrer eller
- gruppen der består af Asp, Ala, Asn, Pro, Leu og Arg.

10 8. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor P2' er en methyleret aminosyre.

9. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor et yderligere anticancermiddel er bundet til peptidet, der omfatter et proteolytisk spaltningsssted for MT-MMP.

15 10. Forbindelsen ifølge krav 9, hvor anticancermidlet er valgt fra gruppen, der består af en antimetabolit, et cytotoxisisk middel, et antiproliferativt middel, 5-fluorouracil, anthracyclin, doxorubicin, vincaalkaloid, taxan, et cytotoxisisk nucleotid, et biotoxin, et radioterapeutisk middel, et hormonalt middel, colchicin, azademethylcolchicin, N-methyl-deacetylcolchicin eller deacetylcolchicin.

20 11. Forbindelsen ifølge krav 10, hvor anticancermidlet er doxorubicin.

25 12. Forbindelse ifølge et hvilket som helst af de foregående krav der yderligere omfatter en capping-gruppe på peptidet, der omfatter det proteolytiske spaltningsssted for MMP, der forhindrer ikke-specifik nedbrydning af peptidet.

30 13. Forbindelse ifølge et hvilket som helst af kravene 2 til 12, hvor forbindelsen har formlen (II)

X-Y-c (II)

hvor c er en capping-gruppe.

**14.** Forbindelsen ifølge krav 13, hvor c er valgt fra gruppen, der består af aliphatiske, aromatiske, polycycliske, carbohydrater og aminosyrer, eventuelt hvor c er en hydrofil gruppe.

5    **15.** Forbindelse ifølge krav 13 eller 14, hvor c er repræsenteret ved formlen  $(c)_n$  hvor n i et helt tal mellem 1 og 5, eventuelt hvor c er en ikke-naturlig aminosyre, og n er 3.

10    **16.** Forbindelse ifølge et hvilket som helst af kravene 2 til 13, hvor forbindelsen har formlen (III)



hvor a er en linker, der er direkte eller indirekte forbundet med X.


15    **17.** Forbindelsen ifølge krav 16, hvor linkeren er en enkelt aminosyre eller aminosyresekvens.

**18.** Forbindelsen ifølge krav 16, hvor forbindelsen har formlen (IV)



hvor c er som defineret i krav 13.


20    **19.** Forbindelsen ifølge krav 13, hvor forbindelsen har formlen (V)



hvor b er en afstandsgruppe, der er direkte eller indirekte bundet til Y.

25    **20.** Forbindelsen ifølge krav 19, hvor afstandsstykket er valgt fra gruppen, der består af en enkelt aminosyre, en aminosyresekvens og en succinyl-gruppe.

**21.** Forbindelse ifølge krav 18, hvor forbindelsen har formlen (VI)



30    hvor b er en afstandsgruppe, der er direkte eller indirekte bundet til Y.

**22.** Forbindelse ifølge et hvilket som helst af kravene 2 til 21, hvor forbindelsen har formlen (VII)

## X-Y-Z (VII)

hvor Z er et anti-cancer middel.

23. Forbindelsen ifølge krav 22, hvor Z er valgt fra gruppen, der består af et va-  
5 skulært ødelæggende middel, en antimetabolit, et cytotoksisk middel, et bio-  
toxin, et radioterapeutisk og et hormonelt middel, og fortrinsvis hvor Z er det cy-  
totokiske middel doxorubicin.

24. Forbindelse ifølge krav 22 eller 23, hvor X er valgt blandt azademethyl-  
10 colchicin, colchicin, azacolchicin, N-methyl-deacetylcolchicin, deacetylcolchicin.

25. Forbindelsen ifølge krav 22, hvor X og Z er valgt blandt azademethyl-  
colchicin, colchicin, azacolchicin, N-methyl-deacetylcolchicin, deacetylcolchicin.

15 26. Forbindelse eller farmaceutisk acceptabelt salt deraf ifølge et hvilket som  
helst af de foregående krav til anvendelse i medicin.

27. Farmaceutisk formulering der omfatter en forbindelse ifølge et hvilket som  
helst af kravene 1-25 og mindst en yderligere farmaceutisk acceptabel exci-  
20 piens, fortyndingsmiddel eller bærer.

28. Farmaceutisk formulering der omfatter en forbindelse ifølge et hvilket som  
helst af kravene 1-25 og et andet terapeutisk middel, eventuelt hvor det andet  
terapeutiske middel er valgt blandt cisplatin, carboplatin, cyclophosphamid,  
25 melphalan, carmustin, methotrexat, 5-fluorouracil, cytarabin, mercaptopurin,  
daunorubicin, doxorubicin, epirubicin, vinblastin, vincristin, dactinomycin C, ta-  
xol, L-asparaginase, G-CSF, etoposid, colchicin, deferoxaminmesylat eller  
camptothecin.

30 29. Forbindelse ifølge et hvilket som helst af kravene 1-25 eller en farmaceutisk  
formulering ifølge krav 27 eller 28 til anvendelse ved behandling af cancer.

**30.** Forbindelse ifølge et hvilket som helst af kravene 1-25 eller en farmaceutisk formulering ifølge krav 27 eller 28 til anvendelse ved behandling af en inflammatorisk lidelse.

5    **31.** Forbindelse ifølge et hvilket som helst af kravene 1-25 eller en farmaceutisk formulering ifølge krav 27 eller 28 til anvendelse ved behandling af hjertesvigt.

**32.** Forbindelse ifølge et hvilket som helst af kravene 1-25 eller en farmaceutisk formulering ifølge krav 27 eller 28 til anvendelse ved behandling af et sår.

# DRAWINGS




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10(a)




FIG. 10(b)




FIG. 10(c)




FIG. 10(d)




FIG. 11

## ICT3053 Ala




FIG. 12




FIG. 13